Table 4.

Cost, effect, cost/effect and incremental cost-effectiveness ratios per person generated after 18 one-year cycles^a

Base CareValues and Variables	Sensitivity Analysis Boundary	Reporting Strategy	Cost ($)	Effect (QALY)	Cost/ Effect ($/QALY)	Descriptive Outcome	ICER ($/QALY)b	See Figure
Base case values		SCr	186,088	11.090	16,779	eGFR more effective and less costly (dominant)	NA
		eGFR	185,933	11.100	16,751
QALY of FP-CKD	Lower	SCr	186,088	11.068	16,813	SCr more cost- effective	4,376	3a
		eGFR	185,933	11.032	16,853
	Upper	SCr	186,088	11.090	16,779	eGFR more effective and less costly (dominant)	NA
		eGFR	185,933	11.100	16,751
Annual probability of progressing from CKD to ESRD	Lower	SCr	177,752	11.276	15,764	SCr more cost- effective	20,289	3b
		eGFR	177,824	11.279	15,765
	Upper	SCr	194,479	10.891	17,857	eGFR more effective and less costly (dominant)	NA
		eGFR	194,142	10.905	17,802
Sensitivity of SCr	Lower	SCr	186,422	11.082	16,822	eGFR more effective and less costly (dominant)	NA	3c
		eGFR	185,933	11.100	16,751
	Upper	SCr	185,725	11.099	16,733	SCr more cost-effective	433,324
		eGFR	185,933	11.100	16,751

QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease, stages 3 to 4 (glomerular filtration rate 15 to 59 ml/min/1.73 m²); FP-CKD, false-positive state for patient without chronic kidney disease, stages 3 to 4; ESRD, end stage renal disease (glomerular filtration rate < 15 ml/min/1.73 m²).

^aResults calculated using base case values and the upper and lower boundary values used in one-way sensitivity analyses.

^bICER results as generated by TreeAge, and differ slightly from ICER values calculated from table due to differing numbers of significant digits.